Introduction {#j_jtim-2020-0007_s_001}
============

Sickle cell disease (SCD) is one of the most CHU Brugmann, Pl Van Gehuchten 4, 1020 Bruxelles, Belgium. frequent genetic blood diseases, with a prevalence of 1/2000 birth in Europe and 1/30 birth in central Africa. SCD occurs with an autosomal mutation in the gene that encodes the β-globin chain, which leads to an abnormal form of hemoglobin (HBS). Some patients are homozygous for this recessive mutation (HB SS). HB SS polymerizes under stressful conditions and leads to sickle-shaped red blood cells with high rigidity and low deformability. This condition causes hemolysis, vaso-occlusive events, and endothelial dysfunction. These are responsible for the cardiovascular complications of SCD mainly represented by pulmonary hypertension and also left and right ventricular dysfunctions, myocardial infarction, iron overload, arrhythmias, and sudden death.^\[[@j_jtim-2020-0007_ref_001]\]^

The impact of this disease on cardiac function is currently debated. The supposed effects could arise from various mechanisms, including dilatation and hypertrophy due to chronic anemia; iron deposition in the myocardium after transfusions; ischemia due to the vaso-occlusion phenomenon; and pulmonary hypertension. All these conditions can lead to myocardial dysfunction, but the extent of dysfunction remains unclear.

Advances in the treatment of SCD have led to extended longevity in these patients. Consequently, the prevalence of heart disease has increased in older individuals with SCD; nearly one-fourth of deaths in this population are due to cardiac involvement.^\[[@j_jtim-2020-0007_ref_002]\]^

Studies on cardiac function in patients with SCD have shown conflicting results. These discrepancies reflect the difficulty in finding a reliable index of function in patients with a chronic overload due to anemia.^\[[@j_jtim-2020-0007_ref_003],\ [@j_jtim-2020-0007_ref_004],\ [@j_jtim-2020-0007_ref_005],\ [@j_jtim-2020-0007_ref_006],\ [@j_jtim-2020-0007_ref_007]\]^ Most methods for evaluating systolic function are highly dependent on volume. This is particularly true in evaluating the left ventricular ejection fraction (LVEF), which remains the most commonly used parameter for evaluating left ventricular systolic function in routine clinical practice.

Speckle tracking echocardiography is a new means of evaluating cardiac function. It is emerging in many fields as a useful tool in the detection of early cardiac function deterioration. The principle of speckle tracking is to measure myocardial strain, based on local shortening, lengthening, and thickening of the muscles. These types of strain cause the displacement of prominent speckles on images of the myocardium. The displacements allow calculations of myocardial strain. Strain can be longitudinal, radial, or circumferential; at present, longitudinal strain is the most widely available and with the more evidence of clinical applications in detecting subclinical left ventricular dysfunction.

Strain is calculated regionally in each myocardial segment. The mean of all regional strains is called the global longitudinal strain (GLS). By convention, when two speckles draw apart from each other, the value is positive; and when two speckles draw towards each other, the value is negative. Therefore, normal systolic longitudinal strain is negative. The GLS calculation is currently available with the most recent-generation echocardiography machines. Although uniformity might be lacking among different vendors, it has been proposed that the GLS could be a useful tool for the detection of early systolic dysfunction in patients under cardiotoxic chemotherapy.^\[[@j_jtim-2020-0007_ref_008]\]^ Moreover, the high reproducibility of GLS measured in the left ventricle (LV-GLS) represents an advantage over the LVEF.^\[[@j_jtim-2020-0007_ref_009],\ [@j_jtim-2020-0007_ref_010]\]^ Moreover, compared with LVEF, LV-GLS is less affected by changes in loading conditions, which makes it a potentially useful tool in patients with SCD due to the chronic overload associated with SCD. However, in this population, studies are rare and results are conflicting.^\[[@j_jtim-2020-0007_ref_011],\ [@j_jtim-2020-0007_ref_012],\ [@j_jtim-2020-0007_ref_013],\ [@j_jtim-2020-0007_ref_014],\ [@j_jtim-2020-0007_ref_015],\ [@j_jtim-2020-0007_ref_016]\]^ More recently, the GLS was found to be altered in a population of patients with β-thalassemia,^\[[@j_jtim-2020-0007_ref_017],[@j_jtim-2020-0007_ref_018]\]^ a hemoglobinopathy that can, in some respects, be compared with SCD.

Study aims {#j_jtim-2020-0007_s_001_s_001}
----------

The primary aim of the present study was to determine whether GLS was abnormal in a monocentric population of adults with SCD, compared with a matched population of healthy individuals. The secondary aim was to investigate correlations between the echocardiographic parameters and the biological and clinical evaluations of patients with SCD.

Materials and methods {#j_jtim-2020-0007_s_002}
=====================

Between September 2014 and September 2015, we prospectively included consecutive patients diagnosed with SCD who were regularly followed at the adult hematology clinic of our institution. The patients were almost all homozygous for SCD, except for one patient who is heterozygous HbS/ß-thalassemia. One patient had a hereditary persistence of fetal hemoglobin (HbF). The Institutional Ethics Committee approved the protocol. All patients provided informed consent. The control group consisted of healthy individuals from the medical community and their relatives. Controls were matched for age and sex with the patients. One patient was excluded because of poor echocardiographic windows.

A single operator with a Philips IE 33 sonograph conducted echocardiographic examinations. We used qlab 9 software for the strain calculations. All echocardiographic examinations in SCD patients were made during steady state (no acute crisis for at least 45 days).

All echocardiographic measurements were made according to the recommendations of the European Society of Cardiology.^\[[@j_jtim-2020-0007_ref_019]\]^ The following measurements were performed for patients and controls: left ventricle (LV) diameter (measured by TM when beam orientation is good, or 2D-guided linear measurement when beam orientation is not good); LVEF, based on the Teichholz and Simpson biplane methods; LV mass measured by Cube formula by linear measurement; LV myocardial performance index (MPI) measured with spectral Doppler; GLS, measured with speckle tracking method; diastolic function, based on the current recommended algorithm^\[[@j_jtim-2020-0007_ref_020]\]^ (diastolic function is considered normal if normal left atrium and/or e' \>8 cm/s, diastolic dysfunction if dilated left atrium *and* e' ≤8 cm/s, further graded to grades 1 to 3 depending on E/A ratio, deceleration time, and e/e' ratio); and the tricuspid regurgitation velocity (TRV), with usual echocardiographic evaluation of pulmonary pressure based on TRV and inferior vena cava (IVC) dimension.

Next, the patient records were reviewed, and the following parameters were recorded: total hemoglobin (Hb), HbF, ferritin, NTproBNP, the number of crises during the past year, walking distance test results, the presence of cerebral lesions on MRIs, the presence of ocular lesions on eye fundus examinations, proteinuria, hypertension, and compliance with treatment.

Statistical analysis {#j_jtim-2020-0007_s_002_s_001}
--------------------

Statistical analyses were performed using SPSS software, version 24. Descriptive data are expressed as the mean ± standard deviation (SD). Univariate analyses of continuous data were compared between groups with the independent T-test or one-way ANOVA. Comparisons between discrete values were performed with the Chi-square test. The results were considered statistically significant when *P*-values were \<0.05. The multivariate analysis was performed with a regressive ANOVA analysis. Correlations between continuous data were analyzed with a bivariate correlation test (Pearson correlation coefficients).

Results {#j_jtim-2020-0007_s_003}
=======

This study included 37 patients with SCD and 34 healthy age- and sex-matched controls. The patient and control groups were similar in age (31 ± 10 years *vs*. 32 ± 10 years, respectively). The sex ratio was similar in the patient and control groups (57% female patients *vs*. 61% female patients, respectively). Most (92%) patients are treated with hydroxyurea, and 70% were considered by their hematologist to be compliant with their treatment. Five patients were treated with chronic transfusions and none were exchanged. Comparison between transfused and non-transfused patient is presented in [Table 4](#j_jtim-2020-0007_tab_004){ref-type="table"}. Four patients had hypertension in the patient group, which was well controlled under treatment (no beta-blocker). No patients had clinical signs of heart failure.

Echocardiographic data in the univariate analysis {#j_jtim-2020-0007_s_003_s_001}
-------------------------------------------------

LVEF was significantly lower in the SCD group than in the control group (Teichholz: 61.8% *vs*. 67.6%, *P* 0.05; biplane Simpson: 61.9% *vs*. 69.3%, *P*\<0.05; [Table 1](#j_jtim-2020-0007_tab_001){ref-type="table"}). However, only one patient had a Simpson LVEF \<50%. MPI was higher (higher values indicate impaired LV function) in the patient group compared with the control group (0.38 *vs*. 0.27; *P*\<0.05), with 14 patients having an altered MPI (\> 0.39). LV mass and left ventricle end diastolic diameter (LVEDD) were higher in the patient group compared with those in the control group (LV mass: 107 g/m^2^ *vs*. 70 g/m^2^, *P*\<0.05; LVEDD: 53 mm *vs*. 46 mm, *P*\<0.05). LV-GLS was significantly lower in the SCD group than in the control group (−19.4% *vs*. --22.4%; *P*\<0.05).

###### 

Univariate analysis results show differences between patients with sickle cell disease (SCD) and healthy controls

  Parameters                  Control       SCD            *P*
  --------------------------- ------------- -------------- ------------
  **LVEF-Teicholz (%)**       67.6 ± 6.9    61\. 8 ± 6.2   0.0004
  **LVEF-Simpson (%)**        69.3 ± 5.3    61.9 ± 7.2     0.00006
  **LVEF \< 50%**             0             1 (2.7 %)      
  **MPI**                     0.27 ± 0.08   0.38 ± 0.16    0.0005
  **LV-GLS (%)**              −22.4 ± 2.8   −19.4 ± 2.4    0.00007
  **LV-GLS \< 18%**           O             8 (21%)        
  **TRV (m/s)**               1.96 ± 0.21   2.24 ± 0.25    0.003
  **E/A**                     1.63 ± 0.35   1.57 ± 0.4     0.499
  **E' (m/s)**                0.16 ± 0.03   0.15 ± 0.04    0.252
  **E/E'**                    5.64 ± 1.34   6.44 ± 1.76    0.054
  **DT (ms)**                 187 ± 36      194 ± 37       0.400
  **Diastolic dysfunction**   0             3 (8%)         0.136
  **LVEDD (mm)**              46 ± 4.9      53 ± 5.1       0.00000012
  **LV mass (g/m^2^)**        70 ± 2.8      107 ± 4.5      0.00000049
  **LVH**                     0             18 (48%)       0.033

The results are expressed as the mean ± standard deviation.

LVEF: left ventricular ejection fraction; MPI: myocardial performance index; LV-GLS: left ventricle global longitudinal strain; TRV: maximal tricuspid regurgitation velocity; E/A: early peak diastolic velocity of the mitral inflow/late peak diastolic velocity of the mitral inflow; E': early diastolic mitral annular tissue Doppler velocity; E/E': ratio between peak velocities of mitral E wave and early diastolic mitral annulus; DT: deceleration time of E mitral wave; LVEDD: left ventricular end-diastolic diameter; LV mass: left ventricular mass; LVH: left ventricular hypertrophy.

LV-GLS was normal (a cutoff value of \>−18% for normal GLS was used based on the proposed cutoff of the vendor and several publications,^\[[@j_jtim-2020-0007_ref_021],[@j_jtim-2020-0007_ref_022]\]^ although clearly established cutoff are not available) in all individuals in the control group, but it was abnormal in eight (21%) patients of the SCD group. Diastolic function was abnormal (type 1 diastole) in three patients (8%) of the SCD group, but normal in the entire control group. The three patients with type 1 diastole were more than 50 years old. One of these patients had iron overload.

TRV was higher in the SCD group than in the control group (2.24 m/s *vs*. 1.96 m/s, *P*\<0.05). However, no patient had pulmonary hypertension (defined as TRV \> 2.8 m/s or systolic pulmonary pressure \<36 mm Hg if IVC is normal).

No difference in echocardiographic parameters was observed between transfused and non-transfused patients, except for MPI ([Table 4](#j_jtim-2020-0007_tab_004){ref-type="table"}).

Echocardiographic data in multivariate analysis {#j_jtim-2020-0007_s_003_s_002}
-----------------------------------------------

The multivariate analysis results ([Table 2](#j_jtim-2020-0007_tab_002){ref-type="table"}) showed that only the LV-GLS, LVEDD, and LV mass remained significantly different between groups.

###### 

Multivariate analysis results show factors significantly related to sickle cell disease (SCD)

  Factors                 Control       SCD            *P* Multivariate
  ----------------------- ------------- -------------- ------------------
  **LVEF-Teicholz (%)**   67.6 ± 6.9    61\. 8 ± 6.2   0.221
  **LVEF-Simpson (%)**    69.3 ± 5.3    61.9 ± 7.2     0.125
  **MPI**                 0.27 ± 0.08   0.38 ± 0.16    0.471
  **LV-GLS (%)**          −22.4 ± 2.8   −19.4 ± 2.4    0.008
  **TRV (m/s)**           1.96 ± 0.21   2.24 ± 0.25    0.148
  **E/A**                 1.63 ± 0.35   1.57 ± 0.4     0.518
  **E' (m/s)**            0.16 ± 0.03   0.15 ± 0.04    0.406
  **E/E'**                5.64 ± 1.34   6.44 ± 1.76    0.236
  **DT (ms)**             187 ± 36      194 ± 37       0.456
  **LVEDD (mm)**          46 ± 4.9      53 ± 5.1       0.004
  **LV mass (g/m^2^)**    70 ± 2.8      107 ± 4.5      0.008

The results are expressed as the mean ± standard deviation.

LVEF: left ventricular ejection fraction; MPI: myocardial performance index; LV-GLS: left ventricle global longitudinal strain; TRV: maximal tricuspid regurgitation velocity; E/A: early peak diastolic velocity of the mitral inflow/late peak diastolic velocity of the mitral inflow; E': early diastolic mitral annular tissue Doppler velocity; E/E': ratio between peak velocities of mitral E wave and early diastolic mitral annulus; DT: deceleration time of E mitral wave; LVEDD: left ventricular end-diastolic diameter; LV mass: left ventricular mass; LVH: left ventricular hypertrophy.

Biological and clinical parameters in patients with SCD {#j_jtim-2020-0007_s_003_s_003}
-------------------------------------------------------

Among patients with SCD, the mean Hb was 9.4 g/dL (range: 6.1--12.2 g/dL) and the mean HbF was 12.7% (range: 1--28.6%). After exclusion of the patient with heterozygous HbS/ß-thalassemia and one patient with a hereditary persistence of HbF, the mean Hb was 9.27 g/dL (range: 6.1--12.2 g/dL). The mean Hb of the 5 transfused patients was 9.53 g/dL, non-significantly different from the mean Hb of the non-transfused patients (*P* = 0.125). Mean ferritin level was 644 μg/L (range: 13--7,267 μg/L) and was higher in the transfused patients (*P* \< 0.05). Iron overload, defined as a ferritin level \>1,000 μg/L, was observed in five patients. The mean NTproBNP level was 154 pg/mL (range: 12--1,685 pg/mL).

Lesions were observed on the cerebral MRIs in 51% of patients. Ocular lesions were observed on the eye fundus examinations in 62% of patients. Proteinuria was observed in 27% of patients. The mean patient walking distance was 66% of the predicted value (range: 33--88%).

Correlations {#j_jtim-2020-0007_s_003_s_004}
------------

LVEF and LV-GLS are correlated (*P* = 0.027). No correlation was observed between NTproBNP level and LVEF (*P* = 0.569), NTproBNP and LV-GLS (*P* = 0.859), walking distance test and LVEF (*P* = 0.2), and walking distance test and LV-GLS (*P* = 0.106). No correlation was observed between LVEF or LV-GLS and age or total Hb (even after exclusion of the two patients with slightly different genotype). LV-GLS and MPI were not correlated (*P* = 0.130). A correlation was observed between ferritin levels and LVEF, but this correlation is certainly due to the outlier with a very high ferritin level; thus, we will not consider it.

Discussion {#j_jtim-2020-0007_s_004}
==========

Our study showed that the echocardiographic parameters of cardiac systolic function were altered in patients with SCD. We showed that GLS was a powerful index of systolic function. Indeed, the GLS was abnormal in 8 (21%) of 37 patients; in contrast, the LVEF was abnormal in only one of these patients. Thus, the GLS appeared to be an effective tool for the detection of early systolic dysfunction in patients with SCD.

Our results were consistent with the results reported by Hammoudi.^\[[@j_jtim-2020-0007_ref_014]\]^ However, Barbosa *et al* ^\[[@j_jtim-2020-0007_ref_013]\]^ did not find a similar alteration in longitudinal strain in a comparable population of patients. In our study, the mean GLS value in the study group was within the normal range; nevertheless, 21% of patients had an abnormal GLS (GLS \< −18%). The GLS of our control group was higher than that reported by Barbosa,^\[[@j_jtim-2020-0007_ref_013]\]^ and it was also higher than the normal range defined by Yingchoncharoen *et al*. in a meta-analysis.^\[[@j_jtim-2020-0007_ref_021]\]^ Our control group comprised healthy young individuals from the medical community. The healthy state of our controls might explain the higher strain displayed in our group compared with the more heterogeneous group analyzed by Yingchoncharoen *et al*.^\[[@j_jtim-2020-0007_ref_021]\]^ and perhaps the control group analyzed by Barbosa *et al*.^\[[@j_jtim-2020-0007_ref_013]\]^; both those groups could have included some individuals with latent dysfunction.

###### 

Clinical and biological parameters

                                Patients with SCD   Controls
  ----------------------------- ------------------- ------------------
  **Parameter**                 Mean (range)        Mean (range)
  **Age (years)**               31 (20--55)         32 (18--54)
  **Weight (kg)**               68.5 (51--90)       66 (52--95)
  **Height (cm)**               170 (156--192)      169 (154--188)
  **Body surface area**         1.8 (1.51--2.14)    1.7 (1.49--2.15)
  **Total Hb (g/dL)**           9.4 (6.1--12.2)     
  **HbF (%)**                   12.7 (1--28.6)      
  **Ferritin (μg/L)**           644.8 (13--7267)    
  **NTproBNP (pg/mL)**          154 (12--1685)      
  **% predicted WDT (%)**       66 (33--88)         
  **Crises during last year**   2 (0--6)            

Hb: hemoglobin; HbF: fetal hemoglobin; WDT: walking distance test.

###### 

Comparison between transfused and non-transfused patients

  Factors                 Non-transfused   Transfused    *P*-Value
  ----------------------- ---------------- ------------- -----------
  **LVEF-Teicholz (%)**   62.6 ± 5.8       57.2 ± 7.4    0.471
  **LVEF-Simpson (%)**    62.4 ± 6.8       56.8 ± 7.9    0.538
  **MPI**                 0.37 ± 0.16      0.47 ± 0.06   0.044
  **LV-GLS (%)**          −19.4 ± 2.3      −19 ± 3.4     0.441
  **TRV (m/s)**           2.24 ± 0.26      2.2 ± 0.14    0.316
  **E/A**                 1.53 ± 0.39      1.77 ± 0.5    0.165
  **E' (m/s)**            0.14± 0.04       0.18 ± 0.02   0.453
  **E/E'**                6.58 ± 1.73      5.12 ± 1.34   0.204
  **DT (ms)**             196 ± 41         182 ± 29      0.238
  **LVEDD (mm)**          51.7 ± 5.3       55 ± 2.7      0.07
  **LV mass (g/m^2^)**    99.2 ± 29        95 ± 16       0.299
  **Age (years)**         31.6 ± 10.9      29 ± 5.9      0.048
  **Body surface area**   1.78 ± 0.16      1.89 ± 0.25   0.177
  **Total Hb (g/dL)**     9.38 ± 1.54      9.53 ± 0.89   0.125
  **Ferritin (μg/L)**     492 ± 724        1636 ± 3164   0.00009

The results are expressed as the mean ± standard deviation.

LVEF: left ventricular ejection fraction; MPI: myocardial performance index; LV-GLS: left ventricle global longitudinal strain; TRV: maximal tricuspid regurgitation velocity; E/A: early peak diastolic velocity of the mitral inflow/late peak diastolic velocity of the mitral inflow; E': early diastolic mitral annular tissue Doppler velocity; E/E': ratio between peak velocities of mitral E wave and early diastolic mitral annulus; DT: deceleration time of E mitral wave; LVEDD: left ventricular end-diastolic diameter; LV mass: left ventricular mass; Hb: hemoglobin.

Bedirian *et al*.,^\[[@j_jtim-2020-0007_ref_015]\]^ in a more recent research, found no difference in LV strain between a group of patients with SCD and a group of patients with other sickle cell diseases (OSCD). However, they found 79% of the patients with SCD to have abnormal strain, which is more than that we found but with a slightly higher cutoff for normal strain. Unlike in our study, their control group is not made of normal subjects; this can explain the absence of difference between their two groups. Another bias of this study is the fact that less than half of the patients with SCD had a LV strain measurement.

In a recent study investigating children (Whipple *et al*.^\[[@j_jtim-2020-0007_ref_016]\]^), no difference in LV strain was observed between patients with SCD and controls, but this population was very young when compared with our population and we can assume that abnormalities of myocardial function are more prevalent as the patients are aging.

Similar to the Barbosa study, we found very few patients with diastolic dysfunction, in contrast to other studies.^\[[@j_jtim-2020-0007_ref_023],\ [@j_jtim-2020-0007_ref_024],\ [@j_jtim-2020-0007_ref_025]\]^ These conflicting results might be explained by the difficulty in defining diastolic dysfunction and the various criteria used in different studies. Diastolic function cannot be determined with a simple index, similar to that used to determine systolic function. Diastolic dysfunction has several grades and can be responsible for heart failure with preserved ejection fraction in the more severe grades. Parameters used to evaluate diastole are dependent on the loading condition, which can be highly variable over time, even in a single patient. In our series, none of the younger patients (aged \<50 years) had an abnormal diastole. Therefore, the findings might reflect the effects of age-related comorbidities.

The MPI (or Tei index) is a historical parameter for evaluating function. The MPI is load independent, and it serves as a marker of both systolic and diastolic functions. It was previously shown that the MPI was impaired in patients with SCD.^\[[@j_jtim-2020-0007_ref_005]\]^ Consistent with that study, we found a higher MPI in patients with SCD than in controls. MPI is also found to be higher in the transfused patients, but these are in great minority so this result is to take with caution.

Consistent with many other studies, we found that LV mass and volume were greater in patients with SCD compared with controls. This finding could be readily explained by the chronic overload associated with SCD. Moreover, it was possible that an iron overload contributed to LV enlargement, because iron overloads can lead to hypertrophy. However, we could not find a correlation between the ferritin levels and hypertrophy.

In our population, we could not find correlation between LV strain and the walking distance test or the NTproBNP level. The small number of patients included in the study might explain these results. Furthermore, walking distance test can also be influenced by anemia, as could be NTproBNP level,^\[[@j_jtim-2020-0007_ref_026]\]^ although we could not find a correlation between these parameters in this study.

The clinical impact of an altered GLS has been demonstrated in some situations, such as chemotherapy.^\[[@j_jtim-2020-0007_ref_008]\]^ Indeed, many studies have shown that patients undergoing chemotherapy exhibited alterations in the LV-GLS before they exhibited reductions in the ejection fraction. Consequently, the GLS measurement is currently recommended for those patients. The technique of measuring the GLS, despite slight variability among vendors, is also studied in many other fields, including coronaropathy, hypertrophic cardiomyopathy, and valvular heart disease. It is currently considered a promising tool for supporting clinical decision-making.^\[[@j_jtim-2020-0007_ref_027]\]^

On the basis of our results, we suggest that the LV-GLS could be a useful parameter for following patients with SCD. However, this application should be evaluated in a larger study, because the many small series on this topic have provided conflicting results. Moreover, the clinical impact of an altered LV-GLS in patients with SCD remains to be assessed; this could be the purpose of a larger study, multicentric, with a long-term follow-up in order to find if LV-GLS could have a prognostic value.

Limitations {#j_jtim-2020-0007_s_004_s_001}
-----------

This study had some limitations. The main limitation was that our study population was quite small; this limited the possibility of finding correlations in clinical and biological parameters. In addition, we designed the study to focus only on the LV-GLS, not radial strain, circumferential strain, or right ventricle strain. We made this choice, because our aim was to use a measure that is currently available in routine echocardiography. However, LV-GLS has no well-established cutoff for normal values and there is still intervendor variability.

Conclusions {#j_jtim-2020-0007_s_005}
===========

Our study showed that GLS, an emerging sensitive reproducible parameter of systolic function, was altered in a significant proportion of patients with sickle cell anemia. Larger studies, probably multicentric, should be conducted to confirm our results and to evaluate whether LV-GLS might have prognostic implications and whether it should be recommended in routine evaluations of these patients.
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